NY-BORN
21.4.2021 15:14:06 CEST | Business Wire | Press release
Total global e-commerce sales represent over $25 trillion in value today, with B2B e-commerce global merchandise value representing more than $12 trillion (Statista). With close to 2 billion websites online as of January 2021, the process of navigating products and determining quality sources can be an arduous, time-consuming, and sometimes impossible task. With billions of individual products and brands represented online and the number of products only increasing by the minute, the importance of curation becomes a critical expertise to support digital transactions. Layer in the changing ways consumers make purchase decisions, including assessing sustainability, integrity, and purpose, and the importance of product strategy is perhaps more vital than ever.
The product curation process creates bespoke collections that appeal to specific demographics and niche customer groups. Modern product curation leverages customer segmentation data and purchase behavior information, followed by personalization techniques to drive product engagement and understanding, create supplemental content around products and ultimately increase transaction value. Today, BORN and Alkeon announce industry veteran Stewart Mancey as Director of E-Concession & Retail Partners, joining a deep bench of global experts from multiple categories. As Director of E-Concession & Retail Partners, Stewart will work closely with Pierre Sapin (Chief Partnership Officer), Brendan Wypich (Chief Design & Product Officer), and Jean-Christophe Chopin (CEO and Founder of BORN and former ex-Verisign and *ETrade EU founder) . Mancey will work with brands and retailers on both Alkeon and BORN. His prestigious training at Harrods and knowledge of the creativity behind each retailer will lead BORN to curate purpose-led lifestyle brands using the filters of integrity, functionality, and desirability.
Stewart states, “Twenty years at Harrods has given me a wonderful experience, fabulous industry contacts, and a deep understanding of the power of curation across multiple categories. As Head of Curation for BORN and Alkeon, I’ll guide the product strategy for both, carefully curating across multiple dimensions that reflect today’s buying priorities and creating the ideal mix representing a cross-section of the best products and companies in the world. We want to take a load of sifting off of buyers and consumers and allow them to experience best-in-class product discovery powered by machine learning, delivered in a personalized experience and a beautiful environment that leverages the latest in technology.”
Stewart started his successful buying career at Harrods when he moved from the shop floor in 2003, working through the buying office in Women’s Superbrands before becoming Buyer of Eveningwear, Armani, and Ralph Lauren after three years. He eventually moved over to Menswear in 2007, where he was Senior Buyer for Men’s Superbrands & Tailoring, overseeing over £10m in renovations and delivering strong growth throughout his four years. In 2011, Stewart added the title of Head of Buying for Sports and managed the London Olympic strategy for Harrods, along with an additional £5m renovation. In 2013, Stewart took over Head of Buying for Furniture, Technology, and Toys and increased his remit in 2017 to include Homewares. After 21 incredibly successful years with Harrods, Stewart today joins BORN and its B2B extension Alkeon. Stewart will be a key player in the vital balance between designed technology and brand culture within both BORN and Alkeon’s market networks.
CEO Jean-Christophe Chopin states, “ Our ambition across BORN and Alkeon is to transform the B2B and B2C supply chains, reimagining discovery, transaction, and connection for both communities. Stewart adds critical and unique expertise to our executive leadership, which is a collection of the best minds in curation, commerce, community, and content. Stewart will contribute his years of knowledge of culture and brands, his deep understanding of the chains of commerce across multiple categories, his leading editorial expertise, and his unmatched Rolodex of brands and creators. We are delighted to have him.”
About BORN:
BORN is a holding company specializing in digital, data-led solutions to optimize retail and wholesale supply chains and reimagine discovery and transactions online. BORN owns Alkeon, a suite of B2B solutions and software products that facilitate digital transformation, as well as BORN.com, a platform that connects a global network of design-led brands and retailers. BORN has also curated and hosted the BORN Awards for 10 years in celebration of purpose led products and creativity. BORN is led by CEO Jean-Christophe Chopin, ex-founder of *ETrade EU and Verisign EU.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom